Stocks of Geron Corporation (NASDAQ:GERN) traded higher last session on Wall Street, down -1.29% to $3.07.
According to the data, Geron Corporation (NASDAQ:GERN) has 6 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.00, we find $5.00. Given the previous closing price of $3.11, this indicates a potential upside of 60.77 percent. GERN stock price is now -3.74% away from the 50-day moving average and 14.76% away from the 200-day moving average. The market capitalization of the company currently stands at $1.58B.
A total of 1 analysts have issued a hold rating and 4 have given it a buy rating. Brokers who have rated the stock have averaged $4.83 as their price target over the next twelve months.
With the price target of $3, Goldman recently initiated with Neutral rating for Geron Corporation (NASDAQ: GERN).
In other news, LAWLIS V BRYAN, Director sold 35,000 shares of the company’s stock on May 11. The stock was sold for $105,000 at an average price of $3.00. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, Director Molineaux Susan sold 35,000 shares of the business’s stock. A total of $86,800 was realized by selling the stock at an average price of $2.48. Insiders disposed of 2,194,719 shares of company stock worth roughly $6.74 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GERN stock. A new stake in Geron Corporation shares was purchased by FAIRMOUNT FUNDS MANAGEMENT LLC during the first quarter worth $21,810,000. ARTAL GROUP S.A. invested $17,087,000 in shares of GERN during the first quarter. In the first quarter, BAKER BROS. ADVISORS LP acquired a new stake in Geron Corporation valued at approximately $9,398,000. POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in GERN for approximately $9,189,000. OCTAGON CAPITAL ADVISORS LP purchased a new stake in GERN valued at around $6,993,000 in the second quarter. In total, there are 242 active investors with 50.50% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $3.1300 for Geron Corporation (NASDAQ: GERN). During the past 12 months, Geron Corporation has had a low of $1.78 and a high of $3.84. As of last week, the company has a debt-to-equity ratio of 0.16, a current ratio of 8.80, and a quick ratio of 8.80. The fifty day moving average price for GERN is $3.1944 and a two-hundred day moving average price translates $2.6786 for the stock.
The latest earnings results from Geron Corporation (NASDAQ: GERN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.07, beating analysts’ expectations of -$0.1 by 0.03. This compares to -$0.09 EPS in the same period last year. The company reported revenue of $21000.0 for the quarter, compared to $0.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -82.93 percent. For the current quarter, analysts expect GERN to generate $70k in revenue.
Geron Corporation(GERN) Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
